To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas.
Additional recommended knowledge
Vildagliptin has been submitted to the U.S. Food and Drug Administration for approval, and will be marketed as Galvus by Novartis. The Food and Drug Administration demanded additional clinical data before it can approve vildagliptin including extra evidence that skin lesions and kidney impairment seen during an early study on animals have not occurred in human trials. Vildagliptin is currently approved for use in the European Union, although it is not yet marketed. The recent finding of liver toxicity problems among clinical trial patients could delay the European debut of this drug.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vildagliptin". A list of authors is available in Wikipedia.|